AP-SA02 Receives Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy designation to intravenous AP-SA02 as an adjunct to antibiotics for complicated methicillin-sensitive or methicillin-resistant Staphylococcus aureus bacteremia. The decision was based on preliminary randomized Phase 1b/2a evidence and adds…
